2026 Q1 -tulosraportti
Vain PDF
37 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 122 | - | - | ||
| 1 700 | - | - | ||
| 3 300 | - | - | ||
| 2 000 | - | - | ||
| 5 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 13.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·10 t sittenWhat do people think they will use the money for?
·9 t sittenJudging by the history, pay interest to NPP Capital.·8 t sittenPerhaps in the same way that AstraZeneca expedited the negotiations and Induct won the Bidra case..? Or perhaps they manage to get into debt with NPP Capital again..?
·10 t sittenDidn't these amateurs have a document some time ago explaining why the lowest issue price should be over 2-2.5 kroner or something?·9 t sittenInduct also reported that AstraZeneca would accelerate negotiations 23.05.2025. Then the share price went up dramatically. Then the founder sold down and was removed from the primary insider list. Then time passes and very little (if anything) seems to materialize in the AstraZeneca relationship. The previous CEO also established two other companies (one seems to have been with the then CFO) at the same address as Induct while he was CEO of Induct. These companies were/are not owned by Induct. A loan agreement has been entered into between Induct and the founder's private company with an interest rate of 18%. This is a related-party transaction that I find no trace of having been approved by the general meeting. In addition, Synnøve Jacobsen claimed in the press that Induct won the Bidra lawsuit, even though it was absolutely not true. There's a lot here that looks absolutely incredibly shady!·8 t sittenThis is just what I currently know. I imagine there is much, much more that I don't know about.
·11 t sittenWill it go down towards 0.90 or is it a good entry today?
·11 t sittenI would have stayed away. And I hope my distrust of the company made people not go all in (while the larger ones could sell out).·7 t sittenDid I say almost 15 mill? Meant approx 20 mill.- ·13 t sittenSad to see. But this was actually self-evident. How the company marketed that they were talking to a potential customer should have been investigated, if you ask me. Good luck going forward.
·11 t sitten · MuokattuHow it was talked about here, an agreement with AstraZeneca, and that it was approaching, and expectations that an agreement would be completed by Q4, only for it to completely disappear (for now at least), I also think is on the border of what should be allowed in a public limited company. A clear picture was created that the agreement was just around the corner, and people bought shares based on this information.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
37 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·10 t sittenWhat do people think they will use the money for?·9 t sittenJudging by the history, pay interest to NPP Capital.·8 t sittenPerhaps in the same way that AstraZeneca expedited the negotiations and Induct won the Bidra case..? Or perhaps they manage to get into debt with NPP Capital again..?
- ·10 t sittenDidn't these amateurs have a document some time ago explaining why the lowest issue price should be over 2-2.5 kroner or something?·9 t sittenInduct also reported that AstraZeneca would accelerate negotiations 23.05.2025. Then the share price went up dramatically. Then the founder sold down and was removed from the primary insider list. Then time passes and very little (if anything) seems to materialize in the AstraZeneca relationship. The previous CEO also established two other companies (one seems to have been with the then CFO) at the same address as Induct while he was CEO of Induct. These companies were/are not owned by Induct. A loan agreement has been entered into between Induct and the founder's private company with an interest rate of 18%. This is a related-party transaction that I find no trace of having been approved by the general meeting. In addition, Synnøve Jacobsen claimed in the press that Induct won the Bidra lawsuit, even though it was absolutely not true. There's a lot here that looks absolutely incredibly shady!·8 t sittenThis is just what I currently know. I imagine there is much, much more that I don't know about.
- ·11 t sittenWill it go down towards 0.90 or is it a good entry today?·11 t sittenI would have stayed away. And I hope my distrust of the company made people not go all in (while the larger ones could sell out).·7 t sittenDid I say almost 15 mill? Meant approx 20 mill.
- ·13 t sittenSad to see. But this was actually self-evident. How the company marketed that they were talking to a potential customer should have been investigated, if you ask me. Good luck going forward.·11 t sitten · MuokattuHow it was talked about here, an agreement with AstraZeneca, and that it was approaching, and expectations that an agreement would be completed by Q4, only for it to completely disappear (for now at least), I also think is on the border of what should be allowed in a public limited company. A clear picture was created that the agreement was just around the corner, and people bought shares based on this information.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 122 | - | - | ||
| 1 700 | - | - | ||
| 3 300 | - | - | ||
| 2 000 | - | - | ||
| 5 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 13.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
2026 Q1 -tulosraportti
Vain PDF
37 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 13.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·10 t sittenWhat do people think they will use the money for?·9 t sittenJudging by the history, pay interest to NPP Capital.·8 t sittenPerhaps in the same way that AstraZeneca expedited the negotiations and Induct won the Bidra case..? Or perhaps they manage to get into debt with NPP Capital again..?
- ·10 t sittenDidn't these amateurs have a document some time ago explaining why the lowest issue price should be over 2-2.5 kroner or something?·9 t sittenInduct also reported that AstraZeneca would accelerate negotiations 23.05.2025. Then the share price went up dramatically. Then the founder sold down and was removed from the primary insider list. Then time passes and very little (if anything) seems to materialize in the AstraZeneca relationship. The previous CEO also established two other companies (one seems to have been with the then CFO) at the same address as Induct while he was CEO of Induct. These companies were/are not owned by Induct. A loan agreement has been entered into between Induct and the founder's private company with an interest rate of 18%. This is a related-party transaction that I find no trace of having been approved by the general meeting. In addition, Synnøve Jacobsen claimed in the press that Induct won the Bidra lawsuit, even though it was absolutely not true. There's a lot here that looks absolutely incredibly shady!·8 t sittenThis is just what I currently know. I imagine there is much, much more that I don't know about.
- ·11 t sittenWill it go down towards 0.90 or is it a good entry today?·11 t sittenI would have stayed away. And I hope my distrust of the company made people not go all in (while the larger ones could sell out).·7 t sittenDid I say almost 15 mill? Meant approx 20 mill.
- ·13 t sittenSad to see. But this was actually self-evident. How the company marketed that they were talking to a potential customer should have been investigated, if you ask me. Good luck going forward.·11 t sitten · MuokattuHow it was talked about here, an agreement with AstraZeneca, and that it was approaching, and expectations that an agreement would be completed by Q4, only for it to completely disappear (for now at least), I also think is on the border of what should be allowed in a public limited company. A clear picture was created that the agreement was just around the corner, and people bought shares based on this information.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 122 | - | - | ||
| 1 700 | - | - | ||
| 3 300 | - | - | ||
| 2 000 | - | - | ||
| 5 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt